Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Total Liabilities (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Total Liabilities readings, the most recent being $27.4 million for Q1 2026.

  • Quarterly Total Liabilities rose 22.26% to $27.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $27.4 million through Mar 2026, up 22.26% year-over-year, with the annual reading at $20.3 million for FY2025, 15.32% down from the prior year.
  • Total Liabilities hit $27.4 million in Q1 2026 for Ovid Therapeutics, up from $20.3 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $56.2 million in Q4 2023 and bottomed at $19.2 million in Q3 2025.
  • Average Total Liabilities over 5 years is $27.6 million, with a median of $23.9 million recorded in 2024.
  • The largest annual shift saw Total Liabilities soared 144.55% in 2023 before it tumbled 58.04% in 2025.
  • Ovid Therapeutics' Total Liabilities stood at $23.0 million in 2022, then soared by 144.55% to $56.2 million in 2023, then crashed by 57.42% to $23.9 million in 2024, then decreased by 15.32% to $20.3 million in 2025, then surged by 34.95% to $27.4 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Total Liabilities are $27.4 million (Q1 2026), $20.3 million (Q4 2025), and $19.2 million (Q3 2025).